Merck & Co. Inc.

09/19/2021 | Press release | Distributed by Public on 09/19/2021 05:59

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast[...]